IDEXX Laboratories stock gained 1.14 percent on September 25

Published on 09/28/2026 at 14:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock reported Q2 2026 revenue of USD 1,216.6 million, up 10 percent. Full-year EPS guidance rose to USD 14.69-14.94.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) was last at USD 519.26 on Nasdaq on September 25, 2026 at 4:00 p.m. ET, up 1.14 percent from the previous close. The veterinary diagnostics company paired that market move with second-quarter 2026 revenue of USD 1,216.6 million, up 10 percent year over year.

Second-quarter growth reaches double digits

According to TradingView, diluted EPS reached USD 4.27 in Q2 2026, an 18 percent reported increase. Operating income rose to USD 425.6 million, while the operating margin reached 35.0 percent, an increase of 140 basis points from the prior-year quarter.

The figures show that recurring diagnostics volume remains the central earnings driver. Companion Animal Group diagnostics recurring revenue increased 11 percent as reported, while the installed base for IDEXX inVue Dx surpassed 9,000 instruments during Q2 2026, according to TradingView.

Guidance moves higher for 2026

Yahoo Finance reported on September 3, 2026 that IDEXX raised its full-year 2026 EPS outlook to USD 14.69-14.94 from USD 14.45-14.90. The company also set revenue guidance at USD 4.70-4.75 billion, compared with the earlier USD 4.68-4.76 billion range.

The next quarterly report is scheduled for November 2, 2026, according to Zacks. Its consensus estimate for the September 2026 quarter is USD 3.71 per share, giving investors a defined checkpoint for the raised annual outlook.

Stock remains below its yearly high

At USD 519.26 on September 25, 2026, IDEXX Laboratories stock stood 32.56 percent below its 52-week high of USD 769.98 and above its 52-week low of USD 500.61. Market capitalization was USD 41.0 billion, with volume of 331,123 shares on that session.

The company also completed its acquisition of CoVetAI on September 16, 2026, integrating veterinary workflow intelligence into its software ecosystem, according to MarketScreener. That move adds a software element to a results profile still led by recurring diagnostic revenue.

September 25 price and valuation

IDEXX Laboratories stock was last at USD 519.26 on Nasdaq on September 25, 2026 at 4:00 p.m. ET, with a 1.14 percent daily gain. The market capitalization was USD 41.0 billion as of the same date.